Abstract
The current study applies a new artificial intelligence (AI) method, ALiX, which is based on interval arithmetic, to analyze and interpret biological data for a clinical problem: identification of biomarkers for cancer diagnosis. The key unique and important feature of this study is that ALiX provides an explanation to our clinical hypothesis in the form of a list of ranked protein biomarkers that identifies which biomarkers are the most significant drivers of the predicted outcome, a capability that is not currently available in other AI methods. Based on the significant drivers, this study identifies a machine learning model and solution for stratifying cancer patients into subtypes that will predict response to treatment.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
